3728 Jinke Rd, Bldg 1, West Wing, Shanghai, China
info@tyligand.com
Tyligand Bioscience Receives IND Clearance from U.S. FDA for TSN084, a Multi-kinase Inhibitor to Address Tumor Resistance to Targeted Therapies
Shanghai, Oct. 16th, 2021 - Tyligand Bioscience, a clinical-stage biotechnology company developing innovative small-molecule therapeutics against drug resistant cancers, today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for its novel drug TSN084 for treating solid tumors. TSN084 is a first-in-class multi-kinase inhibitor targeting CDK8/19 and several other kinases implicated in tumorigenesis and immune evasions. The clinical study is about to start at M.D Anderson Cancer Center in the US soon.
Dr. Tony Zhang, cofounder and CEO of Tyligand Bioscience, commented, “TSN084 is the front runner of the Tyligand pipeline of molecules designed to treat tumors that become resistant to targeted therapies. We hope the potent activities demonstrated by TSN084 against a unique combination of kinase targets responsible for several major cancer hallmarks in preclinical studies can be translated into clinical outcomes for patients suffering NSCLC and TNBC. FDA’s clearance has moved us one step closer towards achieving that goal！”
Founded in 2018, Tyligand Bioscience is a clinical-stage biotechnology company focused on the discovery and development of cancer therapeutics to address drug resistant tumors. Leveraging deep insights into the chemistry of biomolecule phosphorylation, the company has efficiently built a differentiated pipeline and technology platforms including 1st-in-class Dual Action Tumor Immune Agonist (DATIA®) assets and a novel platform for ADC payload design and development.
- Tyligand Bioscience (Shanghai) Limited